We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combining Multiple Laboratory Techniques Provides Deeper Insights into Deadly Brain Tumors

By LabMedica International staff writers
Posted on 15 May 2025

Glioblastoma (GBM) is a highly aggressive primary brain cancer that currently has limited effective treatments. More...

Stereotactic needle biopsies are commonly employed for diagnosis; however, their use is restricted as physicians typically limit the collection of small tumor samples due to the invasive nature of the procedure, which requires sedation with anesthesia. Tumor samples are usually obtained at the start of treatment and, occasionally, at the end. In a groundbreaking study, a team of researchers has shown that doctors can gather extensive information about a patient’s cancer by applying various laboratory techniques to analyze tumor tissue obtained from needle biopsies of glioblastoma. This work, published in Nature Communications, could also have significant implications for diagnosing and studying other types of cancer.

In the study, clinicians from Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and four other institutions injected a virus designed to target and kill glioblastoma cells directly into the tumor. During the same procedure, surgeons collected tumor tissue samples, which were then analyzed using multiple advanced laboratory techniques, including single-cell RNA sequencing, transcriptomics, metabolomics, proteomics, and immune profiling. These techniques allowed the researchers to demonstrate that even small samples of tumor tissue could provide valuable insights into the tumor's biological characteristics, immune interactions, and molecular pathways. Additionally, the study found that the tissue could be grafted onto a mouse model for further examination and analysis.

“This is a concept that expands beyond just brain cancers,” said study co-author Chetan Bettegowda, M.D., Ph.D. “Whenever people do needle biopsies, it has been just sufficient to study if the tissue is cancerous, what type and maybe some very simple molecular characterization. This brings tissue analysis to the modern age. ... Historically [oncologists] haven’t done repeat biopsies because we felt, ‘Oh, what are we going to get that we don’t already know from the original diagnosis?’ It turns out there’s quite a bit to be learned.”

Related Links:
Johns Hopkins Kimmel Cancer Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: INDICAID HPV Urine Test can detect 14 types of high-risk HPV using patented urine DNA concentration technology (Photo courtesy of PHASE Scientific)

World’s First Urine-Based HPV Test to Transform Cervical Cancer Screening

Human papillomavirus (HPV) is a very common sexually transmitted infection (STI) that causes more than 95% of cervical cancer cases. Detection of HPV infections that lead to cellular transformation, followed... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.